AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo

AstraZeneca, Daiichi Sankyo, and Summit Therapeutics will collaborate on a Phase 3 trial to study the combination of datopotamab deruxtecan and ivonescimab for treating triple-negative breast cancer (TNBC). The trial aims to evaluate the efficacy and safety of combining an antibody-drug conjugate with a bispecific immunotherapy. Datopotamab deruxtecan is approved for TNBC in the US, while ivonescimab is under FDA review for non-small cell lung cancer.

AstraZeneca, Daiichi Sankyo, and Summit Therapeutics will test cancer drug Datroway with ivonescimab in a Phase III trial for triple-negative breast cancer. AstraZeneca previously invested $2bn in Summit for joint studies. Each company will share trial costs and retain their drug rights.

AstraZeneca (LON: AZN) and Daiichi Sankyo will collaborate with Summit Therapeutics to test Datroway with ivonescimab in multiple cancer types, including lung and breast cancers. The Phase III trial will focus on triple-negative breast cancer (TNBC). Each company retains rights to its own drug, and no financial terms were disclosed. AstraZeneca shares were down 0.50% at 11,972p.

Daiichi Sankyo (4568.TS), AstraZeneca (AZN), and Summit Therapeutics (SMMT) will collaborate on clinical trials to evaluate Datroway (datopotamab deruxtecan) with ivonescimab for multiple solid tumors, starting with a Phase 3 study for triple-negative breast cancer. Datroway is an approved ADC, while ivonescimab is a novel bispecific antibody. Each company will contribute its medicine and share trial costs. SMMT's stock closed at $16.69, down 1.30%.

Summit Therapeutics (SMMT) partners with Daiichi Sankyo (4568) and AstraZeneca (AZN) to test ivonescimab with Datroway in breast and lung cancer trials. Phase III study in triple-negative breast cancer (TNBC) planned. Each company retains rights to their therapies. Ivonescimab is a novel bispecific antibody targeting PD-1 and VEGF, with ongoing Phase III trials in multiple cancers.

Daiichi Sankyo (TSE: 4568) and AstraZeneca (NYSE: AZN) have partnered with Summit Therapeutics (Nasdaq: SMMT) for a clinical trial. The trial will assess Datroway® in combination with Ivonescimab across various tumor types. The collaboration aims to evaluate the potential of this combination therapy in oncology.